Flu Vaccine Administration in Valley Fever Patients Taking Fluconazole

Vaccine Selection and Safety

The American Academy of Pediatrics recommends inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) should be administered, not the live attenuated intranasal vaccine (LAIV), for patients with valley fever taking fluconazole 2, 1
No evidence exists that antifungal medications like fluconazole interfere with immune responses to inactivated influenza vaccines, according to the Centers for Disease Control and Prevention 1
The inactivated influenza vaccine is safe in patients with fungal infections and those receiving antifungal therapy, as stated by the Morbidity and Mortality Weekly Report 3

The American College of Cardiology and the Centers for Disease Control and Prevention recommend influenza vaccination for patients with chronic medical conditions, including chronic fungal infections, as they are at higher risk for influenza-related complications 4, 5
Vaccination still provides meaningful protection against severe outcomes, including hospitalization and death, for patients on immunosuppressive therapy, although they may develop lower antibody titers compared to healthy adults 6

The vaccine should be administered intramuscularly in the deltoid muscle with a standard 0.5 mL dose, as recommended by the Centers for Disease Control and Prevention 6
Optimal timing is September through November, but vaccination should continue throughout the influenza season as long as vaccine is available, according to the Morbidity and Mortality Weekly Report and the Centers for Disease Control and Prevention 5, 6
Minor illnesses with or without fever do not contraindicate vaccination—only moderate to severe febrile illness should prompt deferral until symptoms resolve, as stated by the American Academy of Pediatrics and the Centers for Disease Control and Prevention 2, 5

The American Academy of Pediatrics recommends not using the live attenuated intranasal influenza vaccine (LAIV) if the patient has significant immunosuppression from their underlying disease or other immunosuppressive medications 2, 6
The Morbidity and Mortality Weekly Report and the American College of Cardiology state that the only absolute contraindications to inactivated influenza vaccine are anaphylactic hypersensitivity to eggs or vaccine components, and history of Guillain-Barré syndrome within 6 weeks of previous influenza vaccination 3, 4

The Centers for Disease Control and Prevention recommends not delaying influenza vaccination unnecessarily—fluconazole is not an immunosuppressive medication and does not require special timing considerations for vaccination 1
Annual revaccination is necessary as immunity declines within one year, particularly important for patients with chronic conditions like valley fever requiring prolonged antifungal therapy, as stated by the Centers for Disease Control and Prevention 6